RPE65 and Retinal dystrophy: A single-dose subretinal injection of voretigene neparvovec administered in each eye is approved in several countries worldwide for the treatment of vision loss in adult and pediatric patients with hereditary retinal dystrophy (IRD), associated with a confirmed biallelic RPE65 mutation and sufficient viable retinal cells [35].